MD2-IN-1 是髓样分化蛋白 2(MD2)的抑制剂,其 KD 值为 189 μM。
靶点Target | Value |
---|---|
MD2 | 189 μM (KD) |
髓样分化蛋白 2(MD2)是 TLR4 的共受体。在这些衍生物中,MD2-IN-1(化合物 20)对脂多糖(LPS)诱导的 TNF-α 和 IL-6 表达具有最强抑制作用。与溶剂对照组相比,单独使用 LPS 大幅增加 TLR4/MD2 复合体的数量,而预先用 MD2-IN-1 治疗可将复合体数量抑制到溶剂对照水平。SPR 分析显示,在剂量依赖性方式下,MD2-IN-1 与重组 rhMD2 蛋白结合表现出明显亲和力,其 KD 值为 189 μM,而黄酮 xanthohumol 与 MD2 结合的 KD 值为 460 μM。预先用不同剂量的 MD2-IN-1 处理会剂量依赖性地减少 FITC-LPS 细胞表面膜上的结合,以平均荧光强度衡量,在 10 μM 时抑制了 65%。预先用 MD2-IN-1 治疗还剂量依赖性地阻断了 MPMs 中的 LPS 引起的 MAPK 磷酸化。
体内研究MD2-IN-1 显著减少了脂多糖(LPS)诱导的肺泡灌洗液中蛋白质浓度的增加。与对照组相比,LPS 治疗组的肺湿/干重比显著升高,并且 MD2-IN-1 处理可以减轻 LPS 引起的肺水肿。LPS 还导致可观察到的肺组织病理学变化,包括炎症浸润、出血、间质性水肿、肺泡壁增厚和肺组织破坏。这些病理变化在 MD2-IN-1 治疗组中得到缓解。
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
3,4-二甲氧基苯乙酮 | 1-(3,4-dimethoxyphenyl)ethanone | 1131-62-0 | C10H12O3 | 180.203 |
3,4,5-三甲氧基苯甲醛 | 3,4,5-trimethoxy-benzaldehyde | 86-81-7 | C10H12O4 | 196.203 |
甲基丁香酚 | 1,2-dimethoxy-4-(2-propenyl)benzene | 93-15-2 | C11H14O2 | 178.231 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | 1,2-dimethoxy-4-(3-(3,4,5-trimethoxyphenyl)prop-1-enyl)benzene | 1215204-90-2 | C20H24O5 | 344.408 |
—— | 3-(3,4,5-trimethoxyphenyl)-1-(3,4-dimethoxyphenyl)propan-1-one | 110148-25-9 | C20H24O6 | 360.407 |
—— | 1-(3,4-dimethoxyphenyl)-3-(3,4,5-trimethoxyphenyl)propane | 56177-97-0 | C20H26O5 | 346.423 |
The pyrazolines give the reactions of aliphatic derivatives, resembling unsaturated compounds in their behavior towards permanganate and nascent hydrogen. This nucleus has been associated with various biological activities, including inflammatory action. Thiazolinone is a heterocyclic compound that contains both sulfur and nitrogen atom with a carbonyl group in their structure. Thiazolinone and their derivatives have attracted continuing interest because of their various biological activities, such as anti-inflammatory, antimicrobial, anti-proliferative, antiviral, anticonvulsant, etc. The aim of the research was to club pyrazoline nucleus with thiazolinone in order to have a significant anti-inflammatory activity. The synthesized compounds were chemically characterized for the establishment of their chemical structures and to evaluate it as an anti-inflammatory agent.
In the present work, eight derivatives of substituted pyrazoline (PT1-PT8) were synthesized by a threestep reaction. The compounds were subjected to spectral analysis by Infrared, Mass, and Nuclear magnetic resonance spectroscopy and elemental analysis data. All the synthesized derivatives were evaluated for their in vivo anti-inflammatory activity. The synthesized derivatives were evaluated for their affinity towards target COX-1 and COX-2, using indomethacin as the reference compound molecular docking visualization through AutoDock Vina.
Compounds PT-1, PT-3, PT-4, and PT-8 exhibited significant anti-inflammatory activity at 3rd hour, being 50.7%, 54.3%, 52.3%, and 57%, respectively, closer to that of the standard drug indomethacin (61.9%). From selected anti-inflammatory targets, the synthesized derivatives exhibited better interaction with COX-1 and COX-2 receptor, where indomethacin showed a docking score of -6.5 kJ/mol, compound PT-1 exhibited the highest docking score of -9.1 kJ/mol for COX-1 and compound PT-8 had a docking score of 9.4 kJ/mol for COX-2.
It was concluded that synthesized derivatives have more interaction with COX-2 receptors in comparison to the COX-1 receptors because the docking score with COX-2 receptors was very good. It is concluded that the synthesized derivatives (PT-1 to PT-8) are potent COX-2 inhibitors.